Polypeptide-Drug Conjugates for Oncology (OncoPDCs)

Self-assembling OncoPDCs represent a new platform of cancer treatment modality, consisting of intrinsically disordered domains, cancer cell receptor-binding sequences, and biologically active agents. These OncoPDCs are designed for image-guided, precision delivery into hard-to-reach solid tumors, including those of the brain and pancreas. By concentrating cytotoxic or immune-modulating payloads within tumor tissues and cancer cells, OncoPDCs enable targeted, localized, and prolonged drug release at the tumor site, optimizing therapeutic outcomes while minimizing side effects.